Editorial
|
| Prevention of therapyrelated malignances in cancer survivors |
|
https://doi.org/10.18632/oncotarget.26781
Gennady A. Belitsky, Kirill I. Kirsanov, Ekaterina A. Lesovaya, and Marianna G. Yakubovskaya
|
| 2114-2115 |
|
| When less is more: Gaining power through gene rearrangement of amplified EGFR |
|
https://doi.org/10.18632/oncotarget.26786
Tomoyuki Koga, Clark C. Chen, and Frank B. Furnari
|
| 2116-2117 |
Research Papers
|
| Microarray and pathway analysis of two COMMADβ derived clones reveal important differences relevant to their developmental capacity invivo |
|
https://doi.org/10.18632/oncotarget.26655
Jabril R. Johnson, Corinne A. Boulanger, Tamaro Hudson, Evan Savage, and Gilbert H. Smith
|
| 2118-2135 |
|
| Pulsed SILACbased proteomic analysis unveils hypoxia and serum starvationinduced de novo protein synthesis with PHD finger protein 14 PHF14 as a hypoxia sensitive epigenetic regulator in cell cycle progression |
|
https://doi.org/10.18632/oncotarget.26669
Jung Eun Park, Shun Wilford Tse, Guo Xue, Christina Assisi, Aida Serra Maqueda, Gallart Palau Xavier Ramon, Jee Keem Low, Oi Lian Kon, Chor Yong Tay, James P. Tam, and Siu Kwan Sze
|
| 2136-2150 |
|
| The BETbromodomain inhibitor JQ1 renders neuroblastoma cells more resistant to NK cellmediated recognition and killing by downregulating ligands for NKG2D and DNAM1 receptors |
|
https://doi.org/10.18632/oncotarget.26736
Irene Veneziani, Doriana Fruci, Mirco Compagnone, Vito Pistoia, Paolo Rossi, and Loredana Cifaldi
|
| 2151-2160 |
|
| Phospholipid profiles and hepatocellular carcinoma risk and prognosis in cirrhotic patients |
|
https://doi.org/10.18632/oncotarget.26738
Alexia Karen Cotte, Vanessa Cottet, Virginie Aires, Thomas Mouillot, Maud Rizk, Sandrine Vinault, Christine Binquet, Jean-Paul Pais de Barros, Patrick Hillon, and Dominique Delmas
|
| 2161-2172 |
|
| Regulation of KrüppelLike Factor 4 KLF4 expression through the transcription factor YinYang 1 YY1 in nonHodgkin Bcell lymphoma |
|
https://doi.org/10.18632/oncotarget.26745
Mario Morales-Martinez, Alberto Valencia-Hipolito, Gabriel G. Vega, Natividad Neri, Maria J. Nambo, Isabel Alvarado, Ivonne Cuadra, Marco A. Duran-Padilla, Otoniel Martinez-Maza, Sara Huerta-Yepez, and Mario I. Vega
|
| 2173-2188 |
|
| Targeting claudin4 enhances CDDPchemosensitivity in gastric cancer |
|
https://doi.org/10.18632/oncotarget.26758
Yukiko Nishiguchi, Rina Fujiwara-Tani, Takamitsu Sasaki, Yi Luo, Hitoshi Ohmori, Shingo Kishi, Shiori Mori, Kei Goto, Wataru Yasui, Masayuki Sho, and Hiroki Kuniyasu
|
| 2189-2202 |
|
| Diagnosis of periprosthetic loosening of total hip and knee arthroplasty using 18FFluoride PET/CT |
|
https://doi.org/10.18632/oncotarget.26762
Sebastian Koob, Florian C. Gaertner, Tom Rainer Jansen, Jan Schmolders, Sascha Gravius, Holger Strunk, Dieter Christian Wirtz, and Markus Essler
|
| 2203-2211 |
|
| Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes |
|
https://doi.org/10.18632/oncotarget.26775
Garima Yagnik, Martin J. Rutowski, Sumedh S. Shah, and Manish K. Aghi
|
| 2212-2223 |
|
| The transcriptomic response to irinotecan in colon carcinoma bearing mice preconditioned by fasting |
|
https://doi.org/10.18632/oncotarget.26776
Franny Jongbloed, Sander A. Huisman, Harry van Steeg, Jeroen L.A. Pennings, Jan N.M. IJzermans, Martijn E.T. Dollé, and Ron W.F. de Bruin
|
| 2224-2234 |
Corrections
|
| Correction: Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reducedintensity conditioning |
|
https://doi.org/10.18632/oncotarget.26806
Zhi Guo, Xiao-dong Liu, and Hui-ren Chen
|
| 2235-2235 |
|
| Correction: Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clearcell renal carcinoma |
|
https://doi.org/10.18632/oncotarget.26807
Roelants Caroline, Giacosa Sofia, Pillet Catherine, Bussat Rémi, Champelovier Pierre, Bastien Olivier, Guyon Laurent, Arnoux Valentin, Cochet Claude, and Filhol Odile
|
| 2236-2236 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
